What should investors diligence first when entering the In Vitro Fertilization Market?

Cycle volume per laboratory, not clinic count. Labs below roughly 300 annual cycles rarely sustain competitive live-birth rates or justify automation capex, which makes throughput the cleanest predictor of asset quality [7]. Read More

How do procurement teams evaluate culture media suppliers in the In Vitro Fertilization Market?

Lot-to-lot consistency data and mouse embryo assay results outweigh unit price. Switching media triggers full protocol revalidation, so buyers weight documented supply continuity and recall history heavily [12]. Read More

Does AI-based embryo grading actually improve outcomes?

Current evidence shows strong concordance with expert embryologists and better inter-operator consistency, but randomized live-birth superiority remains unproven. Its clearest value today is reducing variability in high-volume labs [20]. Read More

What regulatory nuance most affects cross-border donor cycles?

Donor anonymity rules diverge sharply — Spain permits anonymity while the UK mandates identity release at 18. Patients and clinics must reconcile the law of both the treatment country and the child's future residence [13][18]. Read More

How does accreditation variation shape supplier strategy in the In Vitro Fertilization Market?

CAP, ISO 15189, and national ART licences impose different documentation burdens. Suppliers that ship pre-validated protocol packages shorten clinic accreditation timelines and win specification lock-in early [11]. Read More

What integration problems arise when clinics adopt electronic witnessing?

Retrofitting RFID or barcode witnessing into legacy labs frequently breaks existing LIMS workflows and slows staff during the first quarter. Budget for parallel manual witnessing throughout the transition [12]. Read More

Which emerging use cases extend beyond infertility treatment?

Oncofertility preservation and elective oocyte banking now drive a growing share of retrievals. Both generate multi-year cryostorage annuities rather than one-time procedure revenue [14]. Read More

In-Vitro Fertilization (IVF) Market (2026 - 2035)

In Vitro Fertilization Market Research Report: Size, Share, Trend Analysis By Technique (Intra-Cytoplasmic Sperm Injection, Traditional IVF, Preimplantation Genetic Testing, Cryopreservation, Embryo Culture), By Product Type (Instruments, Media, Consumables), By End Users (Fertility Clinics, Hospitals, Research Laboratories), By Patient Type (Male Infertility, Female Infertility, Unexplained Infertility) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2026 To 2035

Forecast Period

2026-2035

CAGR

7.70%

2009 Market Size

26.65 USD Million

2021 Market Size

28.7 USD Million

Healthcare ● Updated August 2026 Report ID: MRFR/HC/1682-CR | Pages: 200 | Author: Satyendra Maurya, Rahul Gotadki

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Summary |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Key Report Takeaways |
1. 2.1 By Product |
2. 2.2 By Procedure and Cycle |
3. 2.3 By Geography
3 Market Size & Forecast (2021–2035) |
1. 3.1 Historical Market Size (2021–2025) |
2. 3.2 Current & Forecast Market Size (2026–2035) |
3. 3.3 Year-over-Year Growth Analysis
4 Driver Impact Analysis |
1. 4.1 Reimbursement Redraws the Demand Curve |
2. 4.2 Demographics Set the Floor |
3. 4.3 Genetic Testing Lifts Revenue per Cycle |
4. 4.4 Employer Benefits Widen the Payer Base
5 Restraints Impact Analysis |
1. 5.1 Affordability Remains the Binding Constraint |
2. 5.2 Talent, Not Equipment, Limits Throughput |
3. 5.3 Rules Differ Across Borders
6 Opportunities |
1. 6.1 Low-Cost Cycle Models for Emerging Economies |
2. 6.2 Outcome Data as a Commercial Asset |
3. 6.3 Fertility Preservation Beyond Infertility |
4. 6.4 Managed-Service Laboratory Contracts |
5. 6.5 Gulf and North African Clinic Buildout
7 Regional Market Share & Country-Level Analysis |
1. 7.1 North America | |
  1. 7.1.1 US | |
  2. 7.1.2 Canada | |
  3. 7.1.3 Mexico |
2. 7.2 Europe | |
  1. 7.2.1 Germany | |
  2. 7.2.2 UK | |
  3. 7.2.3 France | |
  4. 7.2.4 Italy | |
  5. 7.2.5 Spain | |
  6. 7.2.6 Nordic Countries | |
  7. 7.2.7 Russia | |
  8. 7.2.8 Rest of Europe |
3. 7.3 Asia-Pacific | |
  1. 7.3.1 China | |
  2. 7.3.2 India | |
  3. 7.3.3 Japan | |
  4. 7.3.4 South Korea | |
  5. 7.3.5 ASEAN | |
  6. 7.3.6 Rest of Asia-Pacific |
4. 7.4 South America | |
  1. 7.4.1 Brazil | |
  2. 7.4.2 Argentina | |
  3. 7.4.3 Rest of South America |
5. 7.5 Middle East & Africa | |
  1. 7.5.1 Saudi Arabia | |
  2. 7.5.2 UAE | |
  3. 7.5.3 South Africa | |
  4. 7.5.4 Egypt | |
  5. 7.5.5 Rest of Middle East & Africa
8 Future Outlook (2026–2035) |
1. 8.1 Algorithmic Embryo Selection Becomes Standard of Care |
2. 8.2 Platform Economics Reshape Clinic Ownership |
3. 8.3 Cryostorage Turns Into Infrastructure |
4. 8.4 Access Policy Is the Decisive Variable
9 Market Segmentation Analysis |
1. 9.1 By Product | |
  1. 9.1.1 Reagents & Media | |
  2. 9.1.2 Instruments | |
  3. 9.1.3 Consumables & Disposables |
2. 9.2 By Cycle Type | |
  1. 9.2.1 Fresh IVF Cycles – Non-Donor | |
  2. 9.2.2 Frozen IVF Cycles – Non-Donor | |
  3. 9.2.3 Fresh IVF Cycles – Donor | |
  4. 9.2.4 Frozen IVF Cycles – Donor |
3. 9.3 By Procedure Type | |
  1. 9.3.1 Conventional IVF | |
  2. 9.3.2 IVF with ICSI | |
  3. 9.3.3 IVF with PGT/PGD | |
  4. 9.3.4 Other Procedure Types |
4. 9.4 By End User | |
  1. 9.4.1 Fertility Clinics | |
  2. 9.4.2 Hospitals | |
  3. 9.4.3 Surgical Centres | |
  4. 9.4.4 Clinical Research Institutes
10 Competitive Landscape |
1. 10.1 Market Concentration Analysis (2026) |
2. 10.2 Competitive Benchmarking Matrix |
3. 10.3 Company Profiles | |
  1. 10.3.1 Vitrolife Group (Xvivo) | |
  2. 10.3.2 CooperSurgical | |
  3. 10.3.3 Merck KGaA | |
  4. 10.3.4 FUJIFILM Irvine Scientific | |
  5. 10.3.5 Thermo Fisher Scientific | |
  6. 10.3.6 Genea Biomedx | |
  7. 10.3.7 Kitazato Corporation | |
  8. 10.3.8 Esco Medical | |
  9. 10.3.9 Hamilton Thorne | |
  10. 10.3.10 Cook Medical | |
  11. 10.3.11 Ferring Pharmaceuticals | |
  12. 10.3.12 INVO Bioscience
11 Recent News & Developments
12 Report Scope & Methodology
13 Detailed Sources & Citations
14 Frequently Asked Questions
15 LIST OF TABLES |
TABLE 1 Global In Vitro Fertilization Market Size & Forecast, by Revenue (USD Billion), 2021–2035 |
TABLE 2 Global In Vitro Fertilization Market – Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Driver Impact Analysis – Impact Weighting, Geographic Relevance & Timeline |
TABLE 4 Restraint Impact Analysis – Impact Weighting, Geographic Relevance & Timeline |
TABLE 5 Global Market Size, by Region, 2021–2035 (USD Billion) |
TABLE 6 North America Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 7 Europe Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 8 Asia-Pacific Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 9 South America Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 10 Middle East & Africa Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 11 Global Market Size, by Product, 2021–2035 (USD Billion) |
TABLE 12 Global Market Size, by Cycle Type, 2021–2035 (USD Billion) |
TABLE 13 Global Market Size, by Procedure Type, 2021–2035 (USD Billion) |
TABLE 14 Global Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 15 North America Market Size, by Product and Procedure Type, 2021–2035 (USD Billion) |
TABLE 16 Europe Market Size, by Product and Procedure Type, 2021–2035 (USD Billion) |
TABLE 17 Asia-Pacific Market Size, by Product and Procedure Type, 2021–2035 (USD Billion) |
TABLE 18 South America Market Size, by Product and End User, 2021–2035 (USD Billion) |
TABLE 19 Middle East & Africa Market Size, by Product and End User, 2021–2035 (USD Billion) |
TABLE 20 Competitive Benchmarking Matrix – Global In Vitro Fertilization Market, 2026 |
TABLE 21 Company Profiles – Key Players and Strategic Positioning |
TABLE 22 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 23 Report Scope & Methodology Parameters |
TABLE 24 Detailed Sources & Citations Index
16 LIST OF FIGURES |
FIGURE 1 Market Dynamics – Drivers, Restraints and Opportunities Snapshot |
FIGURE 2 Industry Value Chain Analysis – Media, Devices, Laboratory, Clinic, Patient |
FIGURE 3 Porter's Five Forces Analysis |
FIGURE 4 Global Market Size Trend and Forecast, 2021–2035 (USD Billion) |
FIGURE 5 Year-over-Year Growth Curve, 2022–2035 (%) |
FIGURE 6 Market Share by Product, 2025 vs 2035 (%) |
FIGURE 7 Market Share by Cycle Type, 2025 vs 2035 (%) |
FIGURE 8 Market Share by Procedure Type, 2025 (%) |
FIGURE 9 Market Share by End User, 2025 (%) |
FIGURE 10 Regional Revenue Share, 2025 (%) |
FIGURE 11 Regional CAGR Comparison, 2026–2035 (%) |
FIGURE 12 North America Country-Level Share, 2025 (%) |
FIGURE 13 Europe Country-Level Share, 2025 (%) |
FIGURE 14 Asia-Pacific Country-Level Share, 2025 (%) |
FIGURE 15 Competitive Landscape – Estimated Revenue Share Bands, 2026 |
FIGURE 16 Strategic Positioning Matrix – Breadth vs Automation Depth

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Product	Reagents & Media; Instruments; Consumables & Disposables	Reagents & Media	Consumables & Disposables
By Cycle Type	Fresh IVF Cycles – Non-Donor; Frozen IVF Cycles – Non-Donor; Fresh IVF Cycles – Donor; Frozen IVF Cycles – Donor	Fresh IVF Cycles – Non-Donor	Frozen IVF Cycles – Non-Donor
By Procedure Type	Conventional IVF; IVF with ICSI; IVF with PGT/PGD; Other Procedure Types	IVF with ICSI	IVF with PGT/PGD
By End User	Fertility Clinics; Hospitals; Surgical Centres; Clinical Research Institutes	Fertility Clinics	Clinical Research Institutes
By Geography	North America; Europe; Asia-Pacific; South America; Middle East & Africa	North America	Asia-Pacific

Market Segmentation Overview

By Product

Sub-Segment	Key Trend
Reagents & Media	Ready-to-use formulations and extended lot traceability displace in-house preparation
Instruments	Multi-chamber time-lapse incubators replace bench-top units in mid-size labs
Consumables & Disposables	Single-use closed culture pathways reduce contamination and audit burden

Product economics split cleanly between recurring and cyclical demand. Media and disposables generate predictable per-cycle revenue with high switching friction, while instrument sales cluster around clinic expansion waves and the current automation refresh.

By Cycle Type

Sub-Segment	Key Trend
Fresh IVF Cycles – Non-Donor	Remains first-line, but share erodes as freeze-all becomes routine
Frozen IVF Cycles – Non-Donor	Vitrification survival above 95% removes the historical freezing penalty
Fresh IVF Cycles – Donor	Demand tracks advanced maternal age and donor programme availability
Frozen IVF Cycles – Donor	Cross-border donor banking expands cryopreserved supply pools

The decisive shift is temporal. Separating retrieval from transfer lets clinics optimize endometrial timing and insert genetic testing between steps, which is why frozen protocols now outgrow fresh across every major region.

By Procedure Type

Sub-Segment	Key Trend
Conventional IVF	Retains relevance in cost-sensitive and public-funded settings
IVF with ICSI	Applied beyond strict male-factor indication for fertilization certainty
IVF with PGT/PGD	Attach rates climb with maternal age; evidence debate continues
Other Procedure Types	Assisted hatching and in vitro maturation serve defined niches

Procedure mix drives revenue per patient more than cycle counts do. A single retrieval carrying ICSI, biopsy, testing, and cryostorage can generate three to four times the supplier revenue of a conventional cycle.

By End User

Sub-Segment	Key Trend
Fertility Clinics	Chain consolidation centralizes procurement and protocol standards
Hospitals	Oncofertility and complex comorbidity referrals sustain volume
Surgical Centres	Retrieval-only outsourcing models gain traction in capacity-constrained cities
Clinical Research Institutes	Training pipelines and protocol trials expand alongside workforce shortages

Buyer power is migrating upward. As chains absorb independent clinics, purchasing decisions move from individual lab directors to central procurement, which favours suppliers offering validated multi-site packages over best-in-class single products.

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”